Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MS therapy could fight asthma, researchers claim
The team was led by asthma expert Professor Donna Davies, and Professor Stephen Holgate, an asthma expert and co-founder of Synairgen Plc, a UK drug discovery firm to
The team was led by asthma expert Professor Donna Davies, and Professor Stephen Holgate, an asthma expert and co-founder of Synairgen Plc, a UK drug discovery firm to
Under the terms of the agreement, Japan Tobacco (JT) has granted Gilead exclusive rights to develop and commercialize a novel HIV integrase inhibitor, JTK-303, in all countries of
The Swiss approval covers the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Tarceva
Rubella, or German measles, is a viral illness that is spread by sneezing and coughing. Up to 85% of unvaccinated women exposed to the virus in the first
In December 2004, the High Court in London ruled in favor of CAT in the suit regarding royalties of the arthritis drug Humira. However, the Rt Hon Lord
The new study will compare prophylactic combination therapy with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP), with the same combination therapy administered once hepatitis C infection recurs histologically
The St Jude researchers report that TEL2 cooperates with MYC to increase the chance that a certain mutation will occur in precancerous B lymphocytes, permitting these cells to
The case was filed in the US District Court for the Northern District of Illinois, Eastern Division, and charges that advertising claims made by GlaxoSmithKline are false and
The program substantially enhances the worldwide tuberculosis (TB) drug pipeline by adding several novel classes of compounds that use new mechanisms of action. The joint research program consists
The alliance will leverage certain key product candidates in Centocor’s therapeutic protein pipeline, which focuses on cardiovascular disease, immunologic disorders and cancer, using Biolex’ LEX system to economically